Xilio Therapeutics, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing masked immuno-oncology therapies. Its 8-K reports cover financial results, pipeline and business updates, investor presentations, material agreements, capital-structure matters, and clinical or regulatory disclosures tied to its masked I-O programs.
Proxy statements and related 8-K filings describe stockholder votes, director elections, board and committee changes, auditor ratification, equity incentive plans, and amendments affecting common stock. The filing record also includes disclosures related to reverse stock split matters, security-holder rights, director compensation, and governance arrangements for the company’s Delaware corporate structure.
Xilio Therapeutics, Inc. (XLO) is named in a beneficial-ownership disclosure by six reporting persons: Logos Global Management LP, Logos Global Management GP LLC, Logos Opportunities Fund IV LP, Logos Opportunities IV GP LLC, William Arsani and Graham Walmsley. Each reports shared voting and dispositive power over 730,315 shares, representing 9.99% of the class.
The reported securities consist of pre-funded warrants to acquire 476,250 common shares and Series A Warrants to acquire 476,250 common shares; both are subject to a 9.99% beneficial ownership limitation. The percentage calculation uses 6,580,153 common shares outstanding as of August 10, 2026.
Xilio Therapeutics, Inc. (XLO) common stock is covered by an amended ownership report: Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry each report shared beneficial ownership of 731,573 shares, or 9.99%. The amount includes common shares and shares issuable upon exercise of pre-funded warrants. Each reports shared voting and dispositive power, with no sole voting or dispositive power.
The ownership calculation uses 7,063,982 shares outstanding as of November 6, 2026, plus shares issuable upon exercise of pre-funded warrants, subject to a 9.99% beneficial ownership limitation. The reporting persons say the amendment reflects Xilio's reverse stock split and transactions in common stock.
Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross reported shared beneficial ownership of 464,598 Xilio Therapeutics, Inc. (XLO) common shares, equal to 7.06% of the class. Adage Capital Management is the investment manager of Adage Capital Partners, L.P., which directly holds the shares; Atchinson and Gross are identified as managing members of entities in the ownership structure.
Each reporting person reported shared voting and dispositive power over the same 464,598 shares. The percentage was calculated using 6,580,153 shares outstanding as of August 10, 2026.
Xilio Therapeutics, Inc. (XLO) reported third-quarter 2026 collaboration and license revenue of $9.984 million versus $19.066 million in 2025, and net loss of $5.948 million versus $16.287 million. For the first nine months, revenue was $41.324 million versus $30.080 million, net loss was $21.850 million versus $45.396 million, and net cash used in operating activities was $54.899 million versus $2.994 million.
Cash and cash equivalents were $122.182 million as of September 30, 2026; based on current operating plans, Xilio anticipated these funds would cover operating expenses and capital expenditures into the first quarter of 2028. That estimate excludes up to $36.2 million in fourth-quarter 2026 gross proceeds if all outstanding Series C warrants are exercised at their current exercise price, and any potential collaboration payments, including up to $31.0 million in AbbVie milestones and option extension fees that could be achieved through the first half of 2027.
Xilio recently initiated dosing in the XTX501 trial and plans initial Phase 1 data in metastatic non-small cell lung cancer in the fourth quarter of 2027. IND submissions for XTX602 and XTX701 are planned for that quarter, and an efarindodekin alfa option data package for Gilead is expected in the first half of 2027.
Xilio Therapeutics, Inc. (XLO) reported third-quarter 2026 collaboration and license revenue of $9.984 million, versus $19.066 million a year earlier, and a net loss of $5.948 million versus $16.287 million. Loss from operations was $11.749 million, compared with $1.929 million. The quarter included a $4.820 million gain from a change in fair value of common stock warrant liabilities, versus a $15.380 million expense a year earlier. Cash and cash equivalents were $122.182 million as of September 30, 2026.
Xilio dosed the first patient in the Phase 1 portion of the XTX501 trial; initial Phase 1 data are planned for the fourth quarter of 2027. IND submissions for XTX602 and XTX701 are planned for the fourth quarter of 2027. Based on current operating plans, Xilio estimates its existing cash will fund operating expenses and capital expenditures into the first quarter of 2028. That estimate excludes up to $36.2 million in fourth-quarter 2026 gross proceeds if all Series C warrants are exercised, and potential collaboration payments, including up to $31.0 million in AbbVie milestones and option extension fees through the first half of 2027.
Xilio Therapeutics, Inc. (XLO) Chief Medical Officer Yariv Houvras received a direct grant of stock options to acquire 105,000 common shares on October 1, 2026, at an exercise price of $8.91 per share. The options vest as to 25% on September 28, 2027; the remaining 75% vest in 36 equal monthly installments thereafter.
Xilio Therapeutics, Inc. names Yariv Houvras, its chief medical officer, as a reporting person in a Form 3.
StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross report beneficial ownership of Xilio Therapeutics, Inc. common stock. The group may be deemed to beneficially own 628,866 shares of common stock through a combination of equity securities.
The position consists of 343,154 shares issuable upon exercise of pre-funded warrants, 142,856 shares underlying Series A Warrants, and 142,856 shares underlying Series C Warrants. These instruments are subject to a 9.99% Beneficial Ownership Limitation, which restricts exercise above that threshold.
Based on Xilio having 5,982,839 shares outstanding as of May 8, 2026, and including the warrant shares as required under Rule 13d-3(d)(1)(i), the reporting group may be deemed to hold 9.5% of the class. Voting and dispositive powers over all 628,866 warrant-based shares are reported as shared among the reporting persons.
Xilio Therapeutics reported higher collaboration and license revenue, driven by its partnerships with AbbVie and Gilead. Revenue rose to $18.7M for the quarter and $31.3M for the first half of 2026, compared with $8.1M and $11.0M a year earlier, mainly from AbbVie and Gilead milestones and service revenue.
Operating expenses were $22.2M for the quarter and $48.9M for the half, with research and development up year to date as programs advanced and general and administrative slightly lower. Net loss narrowed to $6.4M for the quarter and $15.9M for the half, versus $15.8M and $29.1M in 2025.
Xilio ended June 30, 2026 with $136.0M in cash and cash equivalents and expects this to fund operations for at least twelve months. Deferred revenue from AbbVie and Gilead totaled $35.3M, and common stock warrant liabilities were $30.2M. If all outstanding Series C warrants are exercised at $10.50, the company could receive up to $36.2M in additional gross proceeds in 2026.
Xilio Therapeutics reported second quarter 2026 results and key pipeline updates. Collaboration and license revenue for the quarter was $18.7 million, up from $8.1 million a year earlier, while net loss narrowed to $6.4 million from $15.8 million. Cash and cash equivalents were $136.0 million as of June 30, 2026, and total stockholders’ equity increased to $72.3 million from $35.3 million at year-end 2025.
Operationally, Xilio received FDA clearance of its IND for XTX501, a bispecific PD‑1 / masked IL‑2, enabling initiation of a Phase 1/2 trial in metastatic NSCLC and select solid tumors in the second half of 2026, with initial Phase 1 data in NSCLC planned in the second half of 2027. The company is advancing IND‑enabling studies for masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1, with IND submissions planned in the second half of 2027, and continues a Phase 2 trial of efarindodekin alfa.
Xilio expects its current cash to fund operations into the first quarter of 2028, excluding up to $36.2 million in potential Series C warrant proceeds and up to $31.0 million in potential near‑term milestones and option fees under its AbbVie collaboration.